Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A light in the dark-reframing direct oral anticoagulant pharmacokinetics and pharmacodynamics for near-patient decision-making.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Validation of a whole blood coagulometer sensitive to the direct oral anticoagulants.

Scientific reports·2025
Same author

Outcomes of a proactive first responder system for out-of-hospital cardiac arrests.

Resuscitation·2024
Same author

Outcomes of Warfarin Home INR Monitoring vs Office-Based Monitoring: a Retrospective Claims-Based Analysis.

Journal of general internal medicine·2023
Same author

Comment on: 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults.

Journal of the American Geriatrics Society·2023
Same author

Impact of Hospital-based Multidisciplinary Anticoagulation Stewardship Programs.

Archives of medical research·2022

Related Experiment Video

Updated: May 30, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

New targets for anticoagulation and future perspectives.

Jack Ansell1, David Askin

  • 1Department of Medicine, Lenox Hill Hospital, 100 East 77th St., New York, NY 10075, USA. jansell@lenoxhill.net

Current Drug Discovery Technologies
|August 16, 2011
PubMed
Summary
This summary is machine-generated.

New anticoagulants offer targeted approaches to blood clotting, moving beyond traditional unfractionated heparin (UFH) and vitamin K antagonists (VKA). These advancements include oral direct factor inhibitors, promising safer and more effective treatments.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Related Experiment Videos

Last Updated: May 30, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Area of Science:

  • Pharmacology
  • Hematology
  • Drug Development

Background:

  • Unfractionated heparin (UFH) and vitamin K antagonists (VKA) have been mainstays of anticoagulation for 70 years.
  • These traditional anticoagulants affect multiple coagulation factors broadly.
  • Developments include low molecular weight heparins and fondaparinux with more specific activity.

Purpose of the Study:

  • To review the evolution of anticoagulant drug development.
  • To discuss targeted anticoagulants, including direct thrombin and factor Xa inhibitors.
  • To highlight recent advancements in oral direct factor inhibitors.

Main Methods:

  • Review of existing literature on anticoagulant therapies.
  • Analysis of drug development trends in anticoagulation.
  • Discussion of specific targets within the coagulation cascade.

Main Results:

  • Introduction of parenteral direct thrombin inhibitors for specific patient groups.
  • Emergence of oral direct factor inhibitors (targeting Factor Xa and IIa) as promising VKA alternatives.
  • Exploration of other coagulation factors as potential drug targets.

Conclusions:

  • Anticoagulant therapy is shifting towards more targeted mechanisms.
  • Oral direct factor inhibitors represent a significant advancement in anticoagulation.
  • Continued research into novel coagulation factor targets is ongoing.